Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Implantica receives FDA approval for RefluxStop®

21 August 2026 · By · Wire by Fusion42

Published

21 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 21 August 2026 · Fusion42 review

Implantica has received FDA approval for its medical device RefluxStop®, enabling market entry in the United States for treatment of acid reflux disease.

This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 20 Aug 2026 and 21 Aug 2026.

◆ ◆ The Wire takeaway

Your Medtech product entering the US now faces direct competition from Implantica's RefluxStop®. Prioritise US market readiness and regulatory strategy this quarter to protect local growth.

◆ Coverage

2 sources · first reported 20 Aug 2026 · latest 21 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalmedical-deviceus-market-entryacid-refluximplantica